Discounted Cash Flow (DCF) Analysis Levered

Theseus Pharmaceuticals, Inc. (THRX)

$ 10.155
+0.22 (+2.16%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -------
Revenue (%)
Operating Cash Flow -------
Operating Cash Flow (%)
Capital Expenditure -------
Capital Expenditure (%)
Free Cash Flow -------

Weighted Average Cost Of Capital

Share price $ 10.155
Beta 0.000
Diluted Shares Outstanding 11.92
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 1.834
Total Debt -
Total Equity 121.02
Total Capital 121.02
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -------
Operating Cash Flow -------
Capital Expenditure -------
Free Cash Flow -------
WACC
PV LFCF -------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 1.83
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -8.46
Equity Value -
Shares Outstanding 11.92
Equity Value Per Share -